Login to Your Account

Akeso's checkpoint-blocking MAb draws MSD in $200M agreement

By Cornelia Zou
Staff Writer

Tuesday, December 8, 2015

HONG KONG – Three-year old Chinese novel MAb developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription